[The role of CRISPR screening in leukemia research]

Recent advances in comprehensive genome analysis have contributed to the discovery of several leukemia-related genes; however, the role of mutated genes in the pathogenesis of leukemia remains unknown. Clustered regularly interspaced short palindromic repeats-associated nuclease 9 (CRISPR-Cas9) technology is a powerful tool for genome-wide editing in both coding and noncoding regions. CRISPR screening has enabled high-throughput validation of gene function in diverse tumor processes, including tumor growth and survival, synthetic lethal interactions, therapeutic resistance, and response to immunotherapy, and is actively used in leukemia research. Herein, we discuss recent advances in CRISPR screening in cancer research, focusing on leukemia, and outline application strategies and prospects for CRISPR screening.